News
Stocks rose toward all-time highs as Alphabet Inc.’s results showed solid demand for artificial intelligence, bolstering ...
According to Endpoints News, FDA officials stated that the Center for Biologics Evaluation and Research (CBER) review staff are "unanimous" that Elevidys should never return to market. The report ...
Sarepta Therapeutics (SRPT) stock drops as the company faces potential FDA-mandated studies after safety concerns over its ...
For Sarepta, the hits keep coming, with several downgrades in the past week after it was forced to temporarily take its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results